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Abstract 
Purpose: To investigate the therapeutic effects of Cistanche deserticola Ma. extract (CDME) on 
ovariectomy-induced osteoporosis in rats. 
Methods: Female Sprague-Dawley rats were randomly assigned to a control group and five 
ovariectomy (OVX) subgroups, that is, OVX with vehicle (OVX), OVX with 17ß-estradiol (E2, 25 
µg/kg/day), and OVX with CDME doses (40, 80, or 160 mg/kg/day). Daily oral administration of E2 or 
CDME started 4 weeks after OVX and lasted for 16 weeks. Bone mineral density (BMD) of L4 vertebrae 
and right femur of rats was estimated, The length of each femur was measured, and biochemical 
analysis of serum and urine specimens were performed. 
Results: CDME dose-dependently inhibited the reduction in BMD of L4 vertebrae (0.23 ± 0.02 g/cm3, p 
< 0.05) and femurs (0.20 ± 0.03 g/cm3, p < 0.05) caused by OVX and prevented the deterioration of 
trabecular microarchitecture (p < 0.05), which were accompanied by a significant decrease in skeletal 
remodeling (p < 0.05) as evidenced by the lower levels of bone turnover markers.  
Conclusion: This study indicates that CDME prevents OVX-induced osteoporosis in rats, and could be 
used for treating osteoporosis in elderly women. 
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Osteoporosis is the most common bone disease 
and is characterized by low bone mass, 
microarchitectural deterioration of bone tissue, 
and subsequent bone fragility with susceptibility 
to fracture [1]. Bone fracture risk typically 
increases in the hip, vertebral, and distal forearm 
bones. These fractures are not only painful but 
also disabling, leading to the need for nursing 
home care and increased mortality when 
compared to age matched populations [2]. 
Because of the high morbidity and mortality 
associated with osteoporotic fractures, treatment 
of osteoporosis prioritizes fracture prevention [3]. 
Hormone deficiency is known to impair 
cancellous metaphyseal bone and reduce bone 
mineral density in humans and animals; 
therefore, the estrogen deficiency in 
postmenopausal women has been regarded as a 
critical cause of this population’s susceptibility to 
osteoporosis [4]. Osteoporosis is twice as 
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common in women as in men [5], and 
approximately one in three old women 
experience osteoporotic fracture in her lifetime 
[6,7]. 
 
Clinically, hormone replacement therapy (HRT) 
has been a popular therapeutic strategy 
designed for post-menopausal osteoporosis 
[8,9]. However, the long-term application of HRT 
has potential malignant effects on reproductive 
tissues [10]. Vitamin D and calcium are 
components of bone renewal, but 
supplementation has limited and inconsistent 
effectiveness and is often used in combination 
with other treatments [11].  
 
Cistanche deserticola Ma. has been widely used 
as a kidney tonifying and anti-osteoporosis herb 
for treating osteoporosis for thousands of years 
in China [12-14]. Therefore, this study was 
performed to evaluate the effect of CDME on 




Preparation of Cistanche deserticola Ma. 
extract 
 
The herbal samples of Cistanche deserticola Ma. 
were collected from Bozhou City, Anhui Province 
in China in September 2015. Taxonomic 
identification of the plant was performed by 
Professor Ping He of Zhejiang Chinese Medical 
University, China. A voucher specimen (no. 
CDME 201510012) was deposited in Zhejiang 
Chinese Medical University, China for future 
reference. 
 
One batch of herbal samples of Cistanche 
deserticola Ma. was dried in an oven at 80 ℃. 
Aqueous extract of CDME was obtained by 
steeping the dried Cistanche deserticola Ma. in 
water at 70 oC three times for one hour each. 
Then the extracted fluid was dried in an oven and 
freeze-dried to obtain the last extract. One gram 
powder was equivalent to about 1.8 g crude 
samples. The yield was 55.67 %. 
 
Animals and treatments 
 
Female Sprague-Dawley rats (wt. 200 ± 20 g) 
were provided by the Experimental Animal 
Center of Zhejiang Province (Certificate no. 
SYXK 2003-0004). The animals had free access 
to feed and water, and were allowed to 
acclimatize for at least one week before use. The 
rat experiment was approved by the Animal Care 
and Use Committee of Zhejiang Chinese Medical 
University (approval ref no. 20110506) and was 
carried out in compliance with Directive 
2010/63/EU on the handling of animals used for 
scientific purposes [20]. 
 
Sixty rats were randomly divided into six groups 
of ten individuals: a control group and five 
ovariectomy (OVX) subgroups, that is, OVX with 
vehicle (OVX), OVX with 17ß-estradiol (E2, 25 
g/kg/day), and OVX with CDME (40, 80, or 160 
mg/kg/day). 
 
Bone mineral density (BMD) measurement  
 
The BMD of the L4 vertebrae and right femurs 
was estimated using dual-energy x-ray 
absorptiometry scanning with small animal 
measurement. The measurements were 
expressed as grams of mineral contents per cm2 
of surface area. Scans were performed by the 
same blinded technician. 
 
Three-point bending test 
 
Before mechanical testing, the left femurs were 
slowly thawed at room temperature. The length 
of each femur (distance from the intermalleolar to 
the intercondylar region) was measured with a 
micrometer, and the center of the diaphysis was 
determined. 
 
Biochemical analysis of serum and urine 
specimens 
 
The levels of serum alkaline phosphatase (ALP), 
urinary calcium (U-Ca), urinary phosphorus (U-
P), and urinary creatinine (Cr) were measured on 
an automatic analyzer using a diagnostic reagent 
kit. Serum osteocalcin (OC) concentration was 




The data are expressed as the mean ± standard 
deviation (SD). Statistical analysis was 
performed using one-way ANOVA combined with 
Bonferroni’s multiple comparison test using 
SPSS 16.0. Differences were considered 




BMD of L4 vertebrae and femur 
 
Table 1 demonstrate that OVX significantly 
decreased the BMD in the L4 vertebrae and 
femurs compared to control group (both p < 
0.05). Compared with the OVX group, CDME 
treatment obviously prevented the BMD 
decrease in OVX-induced L4 vertebrae and 
femurs (p < 0.05) in a dose-dependent manner. 
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        Table 1: Effect of CDME on BMD of L4 vertebrae and femurs (n = 10) 
 
Group Dose (mg/kg) BMD of vertebrae (g/cm2) BMD of femurs (g/cm2) 
Control - 0.25±0.02* 0.22±0.04* 
OVX - 0.14±0.03 0.13±0.03 
E2 0.025 0.21±0.04* 0.17±0.04* 
L-DME 40 0.16±0.03* 0.15±0.03* 
M-DME 80 0.20±0.03* 0.18±0.04* 
H-DME 160 0.23±0.02* 0.20±0.03* 
*P < 0.05 and **p < 0.01 versus OVX group. L-CDME: low dose of CDME, M-CDME: medium dose of 
CDME, H-CDME: high dose of CDME 
 
Mechanical characteristics of femur 
 
Table 2 revealed the results of the femur 
mechanical testing. Compared with the control 
group, 16 weeks of estrogen deficiency 
significantly decreased the maximum load and 
maximum stress (both p < 0.05). Higher dosage 
of CDME treatment (80 or 160 mg/kg/day) 
markedly decreased these parameters (both p < 
0.05). E2 also increased the biomechanical 
properties, which were significantly higher than 
those of OVX group (all p < 0.05). 
 
Biochemical profile of serum and urine 
specimens 
 
The effects of CDME on biochemical parameters 
in the serum and urine of OVX rats sees Table 4. 
Compared with control group, the levels of U-
Ca/Cr, U-P/Cr, ALP, and OC were significantly 
increased in the OVX group (all p < 0.05). All 
three CDME doses significantly prevented the 
increases in U-Ca/Cr and ALP levels (all p < 
0.05) in a dose-dependent manner. Higher 
dosage of CDME treatment (80 or 160 
mg/kg/day) significantly prevented the increases 
in U-P/Cr and OC levels (both p < 0.05).  
 
       Table 2: Effect of CDME on mechanical properties of femur (n = 10) 
 
Group Dose (mg/kg) Maximum load (N) Maximum stress (MPa) 
Control - 131.4±6.2* 207.6±5.9* 
OVX - 89.7±5.1 145.4±5.3 
E2 0.025 121.6±4.8* 173.2±4.6* 
L-CDME 40 92.8±4.5 149.6±5.8 
M-CDME 80 103.7±5.8* 166.5±6.1* 
H-CDME 160 117.6±4.9* 187.3±4.8* 
*P < 0.05 and **p < 0.01 versus OVX group. L-CDME: low dose of CDME, M-CDME: medium dose of 
CDME, H-CDME: high dose of CDME. 
 
Table 3: Effect of CDME on morphometric parameters in L4 vertebrae (n = 10) 
 
Group Dosage (mg/kg) Tb-N (1/mm) Tb-Th (mm) Tb-Sp (mm) 
Control - 5.1±0.4* 0.093±0.013* 0.11±0.02* 
OVX - 2.4±0.5 0.059±0.015 0.42±0.04 
E2 0.025 4.3±0.3* 0.084±0.014* 0.22±0.03* 
L-CDME 40 2.6±0.3 0.071±0.013 0.35±0.04 
M-CDME 80 3.7±0.4* 0.075±0.014* 0.27±0.03* 
H-CDME 160 4.5±0.3* 0.086±0.012* 0.17±0.02* 
*P < 0.05 and **p < 0.01 versus OVX group. L-CDME: low dose of CDME, M-CDME: middle 
dose of CDME, H-CDME: high dose of CDME 
 
Table 4: Effect of CDME on biochemical parameters in the serum and urine (n = 10) 
 
Group Dose (mg/kg) U-Ca/Cr (mmol/L) U-P/Cr (mmol/L) ALP (U/L) OC(mmol/L) 
Control - 0.19±0.03* 2.8±0.4* 107.6±9.8* 7.3±0.3* 
OVX - 0.53±0.04 5.4±0.2 232.4±30.5 18.2±0.6 
E2 0.025 0.24±0.03* 3.3±0.3* 123.5±21.3* 10.5±0.4* 
L-CDME 40 0.46±0.04* 4.9±0.4 187.1±19.3* 13.7±0.5 
M-CDME 80 0.37±0.02* 4.1±0.3* 148.3±17.5* 11.4±0.4* 
H-CDME 160 0.25±0.03* 3.2±0.4* 126.7±14.4* 8.8±0.3* 
*P < 0.05 and **p < 0.01 versus OVX group. L-CDME: low dose of CDME, M-CDME: middle dose of CDME, H-
CDME: high dose of CDME 
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The aim of this study was to determine the 
potential effects of Cistanche deserticola Ma. 
extract (CDME) in osteoporosis therapy. Our 
results suggest that CDME could prevent bone 
loss. This study revealed that CDME significantly 
improved bone mass, bone strength, bone 
microarchitecture, and bone turn-over in OVX-
induced osteoporotic rats, which was similar to 
that of E2. These results suggest the potential 
role of CDME as a natural alternative for 
postmenopausal osteoporosis management. 
 
Bone remodeling is the process that mediates 
changes in the traits that influence bone strength. 
Any interruption in bone remodeling, such as 
menopause, will disturb the balance between 
formation and resorption and cause bone mass 
loss [16]. Therefore, we used OVX rats as an 
animal model for human osteoporosis. It has 
been reported that statistically significant bone 
loss can be seen after 30 days of treatment [17], 
so treatment was initiated 4 weeks after OVX. 
Consistent with other studies, OVX caused 
significantly higher body weights in our present 
study, which may be attributed to fat deposition 
caused by the lack of estrogen. Previous studies 
suggest that estrogen plays an important role in 
stimulating the differentiation of progenitor cells 
through the osteoblast lineage but not the 
adipocyte lineage [18]. 
 
Decreased BMD is one of the major factors that 
jeopardizing bone strength, resulting in increased 
susceptibility to fractures [19]. Thus, BMD 
measurement can best predict fracture risk. 
Results in the present study showed that OVX 
reduced BMD in the right femurs and L4 
vertebrae, which are rich in trabecular bone, 
while treatment with CDME dose-dependently 
prevented the decreases in BMD. Although BMD 
is among the strongest predictors of facture 
resistance, both empirical observations and 
theoretical analyses show that the biomechanical 
properties of bone and trabecular 
microarchitecture influenced trabecular bone 
strength as well [20].  
 
The measurement of bone markers plays a role 
in osteoporosis diagnosis and treatment [21]. 
Bone mass loss, as evidenced by enhanced 
levels of ALP, OC, U-Ca/Cr, and U-P/Cr, 
indicated upregulation of bone turnover by OVX. 
The bone turnover markers above were dose-
dependently reversed by CDME, indicating a 
reduction in bone turnover rate after treatment of 
CDME. This study suggests that CDME is 




The findings of this study indicate that CDME 
prevents OVX-induced osteoporosis in rats, and 





Conflict of Interest 
 
No conflict of interest associated with this work. 
 
Contribution of Authors 
 
The authors declare that this work was done by 
the authors named in this article and all liabilities 
pertaining to claims relating to the content of this 




1. Rosen CJ, Bouxsein ML. Mechanisms of disease: is 
osteoporosis the obesity of bone? Nature Clin Pract 
Rheumatol 2006; 2: 35-43.  
2. Lewiecki EM. Osteoporosis. Ann Intern Med. 2011; 155: 
12-13. 
3. Burge R, Dawson-Hughes B, Solomon DH. Incidence 
and economic CDME of osteoporosis-related fractures 
in the United States, 2005-2025. J Bone Min Res 2007; 
22: 465-475. 
4. Favus MJ. Bisphosphonates for osteoporosis. N Engl J 
Med. 2010; 363: 2027–2035. 
5. Marcus R. An expanded overview of postmenopausal 
osteoporosis. J Mus. Neuronal Inte. 2002; 2: 195-197. 
6. Sugerman DT. JAMA patient page. Osteoporosis. JAMA 
2014; 311: 104-105. 
7. Johnell O, Kanis JA. An estimate of the worldwide 
prevalence and disability associated with osteoporotic 
fractures. Osteoporosis Inter. 2006; 17: 1726-1733. 
8. Stevenson JC. Justi cation for the use of HRT in the long-
term prevention of osteoporosis. Maturitas 2005; 51: 
113-126. 
9. Prelevic GM, Kocjan T, Markou A. Hormone replacement 
therapy in postmenopausal women. Minerva 
Endocrinologica 2005; 30: 27-36. 
10. Gray S. Breast cancer and hormone-replacement 
therapy: the Million Women Study. Lancet 2003; 362: 
1332-1333. 
11. Lee JK, Kim KW, Choi JY. Bisphosphonates-related 
osteonecrosis of the jaw in Korea: a preliminary report. J 
Korean Assoc Oral and Maxi. Surgeons 2013; 39: 9-13. 
12. Du SH, Meng Z. The treatment of Cistanche deserticola 
Ma for nephrasthenia syndrome and headache. J Trad. 
Chi. Med. 2004; 45: 250. 
13. Zhang D, Liu Z, Li FM, Xie YJ. The effects of Gushudan 
against osteoporosis. Chinese. Trad. Herbal Drugs 
2008; 39: 1205-1207. 
Zhang et al 
Trop J Pharm Res, September 2016; 15(9): 1933  
 
14. Wong RW, Rabie B, Bendeus M, Hägg U. The effects of 
Rhizoma Curculiginis and Cistanche deserticola Ma 
extracts on bones. Chinese. Med. 2007; 2: 13-14. 
15. European Commission [homepage on the internet]. 
Directive 2010/63/EU on the protection of animals used 
for scientific purposes [cited 2013 Jan 16].Available 
from:http://ec.europa.eu/environment/chemicals/lab_ani
mals/legislation_en.htm. 
16. Zhou Y, Ni Y, Liu Y, Zeng B. The role of simvastatin in 
the osteogenesis of injectable tissue-engineered bone 
based on human adipose-derived stromal cells and 
platelet-rich plasma. Biomaterials 2010; 31: 5325-5335. 
17. Turner RT, Vandersteenhoven JJ, Bell NH. The effects of 
ovariectomy and 17 beta-estradiol on cortical bone 
histomorphometry in growing rats. J Bone and Min. 
Research 1987; 2: 115-122. 
18. Liu DZ, Liang HJ, Chen CH. Comparative 
antiinflammatory characterization of wild fruiting body, 
liquid state fermentation, and solid-state culture of 
Taiwanofungus camphoratus in microglia and the 
mechanism of its action. J Ethnopharmacol, 2007; 113: 
45–53. 
19. McElroy JF, Wade GN. Short- and long-term effects of 
ovariectomy on food intake, body weight, carcass 
composition, and brown adipose tissue in rats. Phys. 
Behav. 1987; 39: 361-365. 
20. Dang ZC, Van Bezooijen RL, Karperien M. Exposure of 
KS483 cells to estrogen enhances osteogenesis and 
inhibits adipogenesis. J Bone Min. Res 2002; 17: 394-
405. 
21. Holick MF. Vitamin D: importance in the prevention of 
cancers, type 1 diabetes, heart disease, and 
osteoporosis. Am J Clin Nutr, 2004; 79: 362–371. 
 
